U.S. Stock News

Preformed Line Products recently reported solid third-quarter 2025 results, with strong revenue growth from its core energy and communications markets while managing tariff-related cost pressures and a one-time pension termination charge. The company’s ability to grow operating income and adjusted earnings while continuing to invest in new manufacturing facilities and acquisitions highlights its underlying financial resilience. We’ll now examine how resilient operating performance amid...

Conference appearance puts Ouster in focus Ouster (OUST) is set to present at the 28th Annual Needham Growth Conference on January 15, 2026 in New York, drawing fresh attention to how investors view the lidar stock today. See our latest analysis for Ouster. At a share price of US$26.36, Ouster’s recent pattern has been mixed, with a 30 day share price return of 18.58% alongside a 90 day share price return decline of 13.69%, while its 1 year total shareholder return of 148.68% and 3 year total...

NextNav (NN) is back in focus after its proposal to the FCC for new rules that could support a terrestrial GPS backup system using 5G spectrum, a move tied directly to critical infrastructure discussions. See our latest analysis for NextNav. NextNav's FCC proposal comes after a choppy year in the stock, with a 1-day share price return of 5.16% and a 7-day share price return of 9.64% contrasting with a 30-day share price return of a 6.49% decline. The 1-year total shareholder return of 20.86%...

China approval puts focus on ARS Pharmaceuticals’ new market opportunity ARS Pharmaceuticals (SPRY) is back on investor radar after partner Pediatrix Therapeutics received approval from China’s National Medical Products Association for community use of neffy, its intranasal epinephrine spray. This decision makes neffy the first government approved epinephrine product for use outside Chinese hospitals. It creates a fresh addressable market and sets up ARS to collect regulatory milestone...

Microvast Holdings recently strengthened its finance leadership, appointing Rodney Worthen as Chief Financial Officer and hiring former NextDecade executive Eric N. Garcia as Chief Accounting Officer, both effective in early January 2026. These appointments bring a blend of corporate finance, investor relations, and Big Four audit experience that could influence how Microvast manages reporting quality, capital allocation, and future expansion decisions. Next, we’ll examine how bringing in a...

VAALCO Energy (EGY) is drawing attention after reporting full year 2025 production and sales volumes around the midpoint and top of guidance, alongside encouraging drilling results at its Etame complex offshore Gabon. See our latest analysis for VAALCO Energy. The production and sales update lands after a strong run in the share price, with a 7 day share price return of 23.29% and a 30 day share price return of 31.20%. The 5 year total shareholder return of 136.12% points to momentum that has...

American Bitcoin’s new disclosure focus American Bitcoin (ABTC) is drawing fresh attention after highlighting more than 5,098 Bitcoin in reserves and rolling out a Bitcoin Yield Metric aimed at giving investors clearer insight into changes in its holdings. See our latest analysis for American Bitcoin. That renewed focus on its 5,098 Bitcoin reserves and the new Bitcoin Yield Metric comes after a tough period, with American Bitcoin’s share price return declining 67.78% over 90 days and 7.87%...

Sila Realty Trust, Inc. recently completed the US$43.1 million acquisition of a fully leased inpatient rehabilitation facility in Oklahoma City, Oklahoma, which has been expanded to 58 beds and is operated under a long-term absolute-net lease with a corporate guaranty. This transaction reinforces Sila Realty Trust’s focus on healthcare real estate anchored by long-duration, necessity-based assets with strong occupancy and limited local competition, aiming to support consistent cash...

What recent performance suggests about Biglari Holdings (BH.A) Recent trading in Biglari Holdings (BH.A) has drawn attention, with the stock showing double digit returns over the past week, month, and past 3 months, prompting investors to reassess what is driving sentiment. See our latest analysis for Biglari Holdings. At a share price of $2,378.72, Biglari Holdings has seen a rapid shift in sentiment, with a 30 day share price return of 35.78% and a 1 year total shareholder return of...

In recent days, HEICO reported past record profitability, broad-based revenue growth, and strong cash generation, underpinned by resilient aviation support demand and continued acquisitions. This combination of robust operating performance, disciplined deal-making, and strong returns on invested capital has reinforced perceptions of HEICO as a high-quality compounder in specialized aerospace and electronics markets. We’ll now examine how HEICO’s record profitability and strong cash...

Aveanna Healthcare Holdings (AVAH) raised its 2025 revenue guidance to a range of US$2.425b to US$2.445b and issued higher preliminary 2026 targets, putting its home based care model firmly in focus for investors. See our latest analysis for Aveanna Healthcare Holdings. Aveanna’s updated guidance comes after a mixed stretch in the market, with a 7 day share price return of 7.33% and a 90 day share price return of a 10.22% decline. Even so, the year to date share price return of 14.11% and a...

William Blair has started covering Enerpac Tool Group (EPAC) with a Market Perform rating, adding a fresh research voice just ahead of the company’s presentation at CJS Securities’ New Ideas for the New Year investor conference. See our latest analysis for Enerpac Tool Group. The William Blair initiation comes after a solid run in the past month, with a 30 day share price return of 9.32%. Over the past year there has been a 7.99% decline in total shareholder return, while the 3 year total...

Earlier in January 2026, Oculis Holding announced that the FDA granted Breakthrough Therapy designation to its neuroprotective candidate Privosegtor for optic neuritis, while also outlining late-stage plans for Privosegtor and its eye-drop OCS-01 in diabetic macular edema. The move positions Oculis as a potential first-mover in neuroprotective treatments for optic neuropathies, a category the company estimates could exceed US$7.00 billion in the U.S. alone. We will now examine how FDA...

JBS has exited its meat snacks joint venture with US jerky maker Jack Link’s, ending a partnership formed in 2010 and allowing Jack Link’s to assume full control of the Meat Snack Partners business after Brazilian regulators received a clearance request. This move points to a reshaping of JBS’s product mix and geographic exposure, as it steps back from Brazil-based meat snack production for export markets. We’ll now examine how JBS’s withdrawal from the Jack Link’s venture reframes its...

TSS (TSSI) drew fresh attention after CEO Darryll E. Dewan and CFO Daniel M. Chism presented at the 28th Annual Needham Growth Conference, giving institutional investors direct access to management and the company’s current positioning. See our latest analysis for TSS. The conference appearance comes at a time when momentum in TSS’s share price has picked up, with a 7 day share price return of 41.27% and a 30 day share price return of 59.60% following a weaker 90 day share price return of...

Perdoceo Education (PRDO) has completed a US$74.8 million share repurchase tranche and announced a new buyback authorization of up to US$100 million, drawing fresh attention to how its stock is being valued. See our latest analysis for Perdoceo Education. The buyback announcements come after a period of mixed share price momentum, with a 7.67% 1 month share price return and an 11.57% 3 month share price decline. Yet longer term total shareholder returns of 16.29% over 1 year and more than 2x...

Earlier in January 2026, Amylyx Pharmaceuticals announced it had selected AMX0318, a long-acting GLP-1 receptor antagonist discovered with Gubra A/S, as a development candidate for post-bariatric hypoglycemia and other rare diseases following extensive preclinical evaluation. The move expands Amylyx’s pipeline into GLP-1 biology and rare metabolic conditions, while triggering up to US$50 million in potential milestones and mid-single digit royalties to Gubra, including US$4 million tied to...

Datwyler recently announced a collaboration with LTS Device Technologies and Stevanato Group to create a pre-verified large-volume subcutaneous drug delivery ecosystem, showcased at Pharmapack in Paris in January 2026. The partnership highlights how Stevanato’s EZ-fill large-volume cartridges can be integrated with advanced plungers and wearable devices to support at-home administration of sensitive therapies. We’ll now explore how this large-volume self-administration platform could...

AnaptysBio, Inc. recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, where President and CEO Daniel R. Faga outlined the company’s latest corporate and pipeline updates. This appearance comes as AnaptysBio reports very large year-over-year improvements in both earnings per share and revenue, alongside higher analyst earnings forecasts that are reshaping investor expectations. We’ll now examine how this combination of very large profitability gains and a...

LightPath Technologies recently presented at the 28th Annual Needham Growth Conference held at The Lotte New York Palace Hotel in New York, drawing interest from investors and industry observers. This conference appearance matters because investors often watch these sessions for updates on product focus, contract pipelines, and management’s execution priorities. We’ll now examine how LightPath’s Needham Growth Conference presentation might influence its investment narrative, particularly...

EHang Holdings Limited has appointed founding team member Shuai Feng as Chief Technology Officer, effective January 14, 2026, formalizing his leadership across pilotless human-carrying eVTOL development, supply chain, and compliance functions. By combining deep product engineering experience with responsibility for procurement, manufacturing scale-up, and safety-focused compliance, Feng’s expanded remit tightly links EHang’s technology roadmap with its commercialization and industrial...

Why CBIZ (CBZ) is on investors’ radar CBIZ (CBZ) has drawn attention after a period of softer share performance, including a 40% decline over the past year. This has prompted investors to reassess the stock against its fundamentals and current valuation. See our latest analysis for CBIZ. CBIZ’s 1 day share price return of 1.4% decline and 7 day share price return of 7.23% decline sit against a 1 year total shareholder return of 39.89% decline. This suggests momentum has faded after earlier...

Without a single clear news event driving it today, Via Transportation (VIA) has still drawn attention after a sharp share price decline over the past month and the past 3 months, prompting closer scrutiny from investors. See our latest analysis for Via Transportation. At a latest share price of $22.90, Via Transportation’s recent slide includes a 7 day share price return of 10.34%, extending to a 30 day share price return of 31.23% and a 90 day share price return of 52.05%, which suggests...

Massimo Group ( NASDAQ:MAMO ) shares have retraced a considerable 27% in the last month, reversing a fair amount of...